These results establish Rab4A as a cell type-specific controller of mitochondrial metabolism and CD98-dependent and KYN-sensitive mTOR activation that mediate therapeutically targetable pro-inflammatory lineage specification in SLE. This evidence concerns the gene RAB4A and systemic lupus erythematosus.